THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19

INTRODUCTION

The coronavirus SARS-Cov-2 pandemic spread through the World with extraordinary speed from its origin in December 2019 in Wuhan, China. As of September 15, 2020, there have been there have been 29,155,581 confirmed cases of COVID-19, including 926,544 deaths worldwide affecting 220 countries and territories (1). This viral and multisystemic illness produces mild or no symptoms in about 80% of infected individuals, however, in about 20% can manifest as pneumonia, which may progress to acute respiratory failure requiring assisted mechanical ventilation in up to 5% of patients (2). Symptomatic COVID-19 exhibits a characteristic sequence of events related to the primary viral attack, manifesting as an influenza-like illness with cough, fever, myalgias and fatigue. In patients destined for severe disease, within seven to 10 days of onset of symptoms, bilateral multiple lobar and subsegmental areas of consolidation are typically seen on chest computed tomography (CT) (See Figure 1) (3). Pneumonia may rapidly progress to acute respiratory failure with elevated cytokines suggesting an immune reaction as probable cause (4). Additionally, a coagulopathy develops and can affect the lungs and other organs, including triggering cerebrovascular thrombosis (5).

• Download figure
• Open in new tab

Figure 1: THE PHASES OF COVID-19 INFECTION.

Asymptomatic viremia typically lasts for 5 days followed by symptoms of an upper respiratory infection. The immune response takes hold over the next week. Pneumonic infiltrates begin to appear. In patients destined for severe infection, a hyperinflammatory reaction takes hold, leading to worsening of pulmonary symptoms, hypoxia, and potentially acute respiratory distress syndrome.

In mainland China, vigorous efforts to contain the spread of COVID-19 by home isolation, closure of business activity, travel bans, and tracking and control of contacts succeeded. As of Sept 15, China has had 90,718 confirmed cases with 4,742 deaths, but the number of new cases declined to very low levels since April (1). Similar measures contained the epidemic in Korea, Taiwan and in New Zealand (1). In Hong Kong, one of the most densely populated areas in the world, universal masking, immediate hospitalization and early antiviral treatment for all confirmed cases have minimized the number of confirmed COVID-19 cases to 4972 in a 7.5 million population with less than 3% requiring ICU care, and 101 fatalities (6). However, the disease has not been similarly controlled in the rest of the World, particularly the United States (USA) where, despite only a fifth of the population of China, there have been 6,462,078 confirmed cases of COVID-19 with 193,119 deaths as of September 15, 2020 (1). In the USA, as in China, the response to the pandemic was through reduction of person-to-person contact by social distancing. Beginning in early March, social gatherings and meetings ended; schools and businesses were closed along with recreation areas, parks, and beaches. These efforts blunted the spread of the disease, but not with the results achieved in China. Due to economic pressures, epidemiologic containment was relaxed resulting in a significant surge surpassing the original April peak.

Facing the growing crisis in early January, Chinese health authorities began treating patients empirically with agents with demonstrated in vitro antiviral activity against coronaviruses and those used durprior outbreaks of SARS 2003, H1N1 influenza of 2009 and MERS 2015 in Asia (7). The medications used included the antimalarial drugs hydroxychloroquine (HCQ) and chloroquine, the human immuno-deficiency virus (HIV) protease inhibitor lopanovir-ritanovir (LPV/r), the Russian antiviral umifenovir, and traditional Chinese medical approaches (8). Subsequently, the antimalarials were widely used to treat COVID-19 throughout the world, despite cautions from numerous regulatory bodies. The scientific basis for their use was in vitro evidence of an effect on blocking viral endosomal penetration, as well as a known suppressive benefit on undesirable autoimmune effects (9). Clinical studies thus far have been controversial.

Multiple vaccines are in clinical trials to assess safety and effectiveness, but these studies are unlikely to complete Phase III testing and proceed to mass vaccination until early 2021. In view of the continuing daily increase in new cases and deaths, our goal was to assess the options we have at the present time for release of pharmacologic agents to treat and to prevent COVID-19 while awaiting widespread immunization.

METHODS

CLINICAL TRIALS: We reviewed up-to-date information from several sources to identify potential treatments for COVID-19: The Reagan-Udall Expanded Access Navigator COVID-19 Treatment Hub was used to track the efforts of companies to develop therapeutic interventions. We searched for investigational trials which had begun active recruitment as of April 1, 2020, reasoning that the timeline to implement treatments in the second half of 2020 would require completion by September 1.We further searched for all trials with reported completed enrollment as of September 1, 2020. We used (A) covid-trials.org, a registry to collate all trials in real time with data pulled from the International Clinical Trials Registry Platform and all major national registries (10).We cross validated information on (B) clinicaltrials.gov the registry of clinical trials information maintained by the United States National Library of Medicine. We further cross referenced the trials on (C) the World Health Organization’s International Clinical Trials Registry Platform (WHO ICTRP).We excluded studies which were clearly observational for treatment purposes, with no randomization, control or comparison group. We further set a cutoff of 100 for numbers of subjects since smaller trial size typically lacks statistical power to enable regulatory approval. For each trial selected, we documented the setting of patient contact, either hospital or outpatient, the type of control procedure, the date the trial was initially registered, and the proposed date of completion of enrollment.

PUBLISHED TRIAL RESULTS: Our search was carried on the week of September 1 2020. We identified all publications on pubmed.gov to find peer reviewed articles and on medRxiv to find preprint reports. We further carried out daily Google™ searches on each potential treatment to find preliminary reports, typically presented as press releases, reviewed by a journalist.

VIRTUAL DISCUSSIONS AMONG CO-AUTHORS: We used the preprint server medRxiv to post a systematic analysis of the development of therapeutic interventions for COVID-19 in order to stimulate discussion of the manuscript and allow widespread “open source” input (11). Successive versions have been posted periodically beginning in late May, 2020 and continuing to date.

RESULTS

REVIEW OF CURRENT TRIALS: As of our cutoff date of April 1, we identified 781 trials worldwide meeting our review criteria. Approximately half the trials were registered in mainland China, and 103 trials were registered in the U.S.A. There were 553 trials in the recruitment process (SUPPLEMENTARY TABLE 1). We found 409 trials meeting the minimum requirement of 100 subjects which were recruiting as of April 1. The WHO organized a megatrial, appropriately named Solidarity, to assess four separate treatment options in hospitalized patients: (a) Remdesivir, an intravenously administered inhibitor of RNA polymerase; (b) LPV/R; (c) LPV/R plus Interferon β-1a; and (d) HCQ or Chloro-quine (12). Completion of enrollment is estimated in the first quarter of 2021. However, the antimalarial and LPV/R drug arms of the Solidarity study were terminated after review suggested no benefit in hospitalized patients.

OTHER TRIALS WITH THE SOLIDARITY AGENTS: In addition to and independent from the Solidarity trial, we found 46 ongoing trials of HCQ, 11 trials of LPV/r and 8 trials of interferons (See SUPPLEMENTARY TABLE 2). There were 21 HCQ trials focused solely on hospitalized patients. Ten HCQ trials focused on prevention of the disease. There were seven HCQ trials conducted on ambulatory patients with diagnosed mild disease.

Two prevention trials with LPV/r are currently enrolling, with earliest enrollment completion in the second quarter of 2020 for one and the third quarter for the other. There is one outpatient active comparison trial with HCQ with proposed enrollment end in the second quarter of 2020. There is one large interferon prevention trial scheduled to complete enrollment in the second quarter of 2020.

ANTIVIRAL AGENTS: SARS-Cov-2 attacks cells by binding of the spike protein to the host cell ACE2 receptor. A specific serine protease TMPRSS2 then activates membrane fusion allowing viral RNA to enter the cell to be replicated with release of multiple virions. Numerous antiviral agents are now in active trials (See SUPPLEMENTARY TABLE 3). In addition to remdesivir, trials are ongoing with favipiravir (FVP), an oral inhibitor of the RNA polymerase, and with umifenovir, a membrane lipid fusion inhibitor with broad antiviral properties and with camostat which is a potent serine protease inhibitor (13,14). A very large, multicenter, prevention trial for hospital workers exposed to COVID-19 in Spain, involves 4000 subjects who will be randomized to emicitrabine/tenofovir, an HIV agent, or to HCQ or to placebo. The trial has planned to meet its enrollment goal by the beginning of the third quarter of 2020.

IMMUNE MODULATORS: Many trials are focusing on inhibitors of IL1 and IL6, as well as other agents currently approved for treatment for rheumatoid arthritis and other autoimmune conditions to suppress the cytokine storm of COVID-19 (See SUPPLEMENTARY TABLE 4). These trials are all directed at severely ill COVID-19 inpatients. There is a large multicenter, placebo-controlled trial of colchicine in non-severely ill outpatients scheduled to enroll 6000 individuals by end of the third quarter of 2020.

DISCUSSION

SARS-Cov-2 overwhelmed medical preparedness for the pandemic. Current projections are for a continuation of new cases and deaths through the end of 2020 (90,91). Clinical trials to date have focused on hospitalized patients to try to prevent death. The modalities currently having emergency approval for treatment are solely directed at hospitalized patients. It is hoped that the use of remdesivir, convalescent plasma, anticoagulation and improved management of COVID-19 respiratory failure will lower the present rate of mortality which in some series has been as low as 6% but in most hospitals still approaches 20% (74). However, it is essential to prevent and to treat the initial viral infection so that hospitalization can be avoided. We face a dilemma in having no current prevention nor treatment for outpatients with mild to moderate disease, constituting 80% of the infected population and the primary mode of spread of SARS-Cov-2. The lessons learned in very sick hospitalized patients do not necessarily apply to the earlier viremic phase of the disease. Antiviral agents, such as remdesivir and favipiravir, and convalescent plasma are likely to be most effective during the early stage of viremia, which is prehospitalization.

Vaccines have been the sole hope held out by public health authorities to arrest SARS-Cov-2. Progress on vaccine development has been rapid, but the speed of development does not reduce the challenges of developing a vaccine to be administered to hundreds of millions of people. Certainly the 30 years of as yet unsuccessful efforts to produce an AIDS vaccine illustrate the worst case difficulties. Although neutralizing antibodies and memory T cells can be produced by the vaccine candidate, the demonstration of true protection requires observation and long-term follow-up of an exposed vaccinated population. No matter how rapidly a vaccine advances to Phase III testing, the duration of follow-up cannot be shortened, and for SARS-Cov-2 possibly prolonged due to several factors. First, there is a risk of immune enhancement of infection which occurs when induced antibodies increase entry and internalization of virus into myeloid cells (92). This major complication struck the newly developed dengue vaccine in 2017 (93). Second, the sinister autoimmune pathogenicity of SARS-Cov-2 raises the risk of delayed long-term harm if the virus is not fully and immediately eradicated by the initial immune response to the vaccine. Finally, the duration of protection is an open question. Studies of recurrent coronavirus infections suggest that infection may confer immunity for less than a year (94). For these reasons of needed long term safety observation, the deployment of an effective vaccine could be delayed.

Shortages of testing supplies in the United States have thus far limited the ability to positively diagnose the disease, resulting in the recommendation of home quarantine for the majority of patients with suspicious symptoms. Those shortages are being remedied. Now, there is a need for therapeutic interventions which can be used to treat outpatients with positive COVID-19 tests at the time of initial symptoms, not waiting for deterioration requiring hospital care. The Marseille group demonstrated that it was possible to treat all outpatients with a positive COVID-19 test early in the viremic phase (27). They provided clinical and virologic data, but without a well-defined control group to justify their treatment with HCQ plus AZM. The NYU group treated all hospitalized patients with HCQ and AZM, and showed an impressive effect of addition of zinc sulfate, but they had no control group for HCQ plus AZM. Remdesivir administered intravenously for five days is not a practical daily outpatient treatment; Gilead© is attempting to develop an inhaled remdesivir formulation, but those efforts are only now beginning. Favipiravir, a tablet, could be used in early stages of infection and has now been released in Russia and in India, but not in the United States. It has known embryogenic risks, so its use requires restrictions on women of childbearing potential, as is the case with tretinoin for acne and thalidomide for multiple myeloma. Trials with camostat, the serine protease inhibitor, capable of blocking cell entry of SARS-Cov-2, are not due to end till the third or fourth quarter of the year. Similarly, a prevention trial with colchicine is not scheduled to end until the fourth quarter of 2020. The Solidarity Trial interferon arm is not scheduled to complete enrollment until 2021 and is a study of hospitalized patients. Convalescent plasma has been approved for emergency use in hospitalized patients. Potentially an infusion could be delivered to outpatients. Monoclonal antibodies based on the same principle are under study to prevent nursing home outbreaks, and could potentially be delivered to ambulatory patients. But, at this time, no outpatient therapy has been proven safe and effective in a phase III randomized, placebo-controlled study. There are strong arguments to avoid emergency use of agents until trials are completed and analyzed, but the agents suggested are not new. Most are drugs like the interferons, marketed and available for other conditions and with well-known safety profiles. There is a clear need for outpatient therapeutic intervention now.

There is a precedent to resolve the conflict between immediate clinical need and the requirements for rigorous controlled trials to prove efficacy. We should remember that the greatest success in fighting a pandemic occurred over the past two decades in the battle against the HIV virus which causes AIDS. AIDS was first recognized in 1981 in the MSM (men who have sex with men) community (95). The disease was considered a death sentence. There was widespread fear because there was no treatment, and projections of infection escalated into the millions. The first AIDS remedy was azidothymidine (AZT), synthesized in 1964 in the hope that it would combat cancer. Twenty years later Dr. Samuel Broder, head of the National Cancer Institute, showed that the drug had activity against the HIV virus in vitro (96). Burroughs Wellcome launched a rapidly conceived trial with just 300 patients. They stopped the trial in 16 weeks claiming that more patients survived on AZT. The FDA came under enormous pressure from AIDS activists to make the drug available, and it was approved on March 19, 1987, with only that one trial. It had taken 20 months for the FDA to give approval to release the drug. To this day, the design and results of the trial remain controversial.

The LGBT community continued to battle for early release of other medications to combat the AIDS pandemic. On October 11, 1988, a massive protest occurred at the FDA. It was back then Dr. Anthony Fauci who publicly advanced the idea of a parallel track to make drugs widely available even while studies are progressing: “Clearly, the standard approach to the design of clinical trials—that is, rigid eligibility criteria as well as the strict regulatory aspects that attend clinical trial investigations and drug approval—was not well-suited to a novel, largely fatal disease such as this with no effective treatments, and we had many intense discussions about how to make that approach more flexible and ethically sound. One example, which I and others worked closely with the AIDS activists to develop, was called a parallel track for clinical trials. The parallel track concept, which the United States Food and Drug Administration ultimately came to support, meant that there would be the standard type of highly controlled admission criteria and data collection for the clinical trial of a particular drug. In parallel, however, the drug also could be made available to those who did not meet the trial’s strict admission criteria but were still in dire need of any potentially effective intervention, however unproven, for this deadly disease” (97).

The parallel track advocated by Dr. Fauci was adopted. Today, there are 41 drugs or combinations approved by the FDA to treat and to prevent HIV infection. There is still no vaccine. There are now an estimated 1.1 million patients with HIV in the United States, most enjoying near normal life expectancy thanks to the antiviral agents. The CDC has contributed greatly to limit the spread of HIV by advocating safe sex practices, but social distancing is not the norm for HIV. Rather “treatment as prevention” for people with HIV using highly active antiretroviral regimens to prevent transmission as well as pre-exposure prophylaxis with a daily antiviral combination pill are currently endorsed by the CDC and adopted in wide segments of the at risk population (98).

In this pandemic crisis, we appeal to public health authorities to change the dynamic of current studies to outpatient care and to cross institutional, commercial and international boundaries to collate and combine all randomized controlled data submitted for all agents in Europe, China, Russia, Japan, India and other countries, and by competing companies, whether officially published, posted on line, or unpublished to finalize confirmatory results. The Solidarity Trial is a model of what could and should be done to unify a worldwide effort to pursue randomized controlled studies in outpatients. At the same time, agents with favorable preliminary results and no safety issues should be made available through a parallel track. In Russia and India, the parallel track has been fully implemented, with FVP now offered as treatment throughout both countries, even as further confirmatory controlled trials proceed. Interferon β is one of the remaining randomized controlled Solidarity Trial options and is widely available in most countries. If vaccines can be brought forward now, it is reasonable to authorize their use at present in very large parallel track studies in at risk populations, such as healthcare workers and the elderly. China has begun vaccinating their military with one of their vaccines. Russia is proceeding to a voluntary vaccination program. The United Kingdom and the U.S. Centers for Disease Control are considering an emergency authorization program for vaccines before conclusion of the ongoing Phase 3 trials. However, it is unwise to rely solely on the hope for an eventual vaccination program to stop SARS-Cov2. Antiviral medication has succeeded in limiting HIV. Antiviral medication is just as important as annual vaccination for control of influenza. It is necessary for public health authorities to make hard decisions now despite limited current data and offer outpatient treatments on a broad front with no further delay.